<SEC-DOCUMENT>0000929638-25-004298.txt : 20251114
<SEC-HEADER>0000929638-25-004298.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114161050
ACCESSION NUMBER:		0000929638-25-004298
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TENAX THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0000034956
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				262593535
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-58467
		FILM NUMBER:		251486189

	BUSINESS ADDRESS:	
		STREET 1:		101 GLEN LENNOX DRIVE
		STREET 2:		SUITE 300
		CITY:			CHAPEL HILL
		STATE:			NC
		ZIP:			27517
		BUSINESS PHONE:		919-855-2100

	MAIL ADDRESS:	
		STREET 1:		101 GLEN LENNOX DRIVE
		STREET 2:		SUITE 300
		CITY:			CHAPEL HILL
		STATE:			NC
		ZIP:			27517

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OXYGEN BIOTHERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20080703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SYNTHETIC BLOOD INTERNATIONAL INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SINEQUANON CORP
		DATE OF NAME CHANGE:	19901219

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lind Global Fund II LP
		CENTRAL INDEX KEY:			0001871665
		ORGANIZATION NAME:           	
		EIN:				863914253
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		444 MADISON AVENUE
		STREET 2:		41ST FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		646-701-7428

	MAIL ADDRESS:	
		STREET 1:		444 MADISON AVENUE
		STREET 2:		41ST FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0000929638-24-003915</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001871665</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>2</amendmentNo>
<securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>09/30/2025</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0000034956</issuerCik>
<issuerName>TENAX THERAPEUTICS, INC.</issuerName>
<issuerCusip>88032L605</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>101 Glen Lennox Drive</com:street1>
<com:street2>Suite 300</com:street2>
<com:city>Chapel Hill</com:city>
<com:stateOrCountry>NC</com:stateOrCountry>
<com:zipCode>27517</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Lind Global Fund II LP</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>442480</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>442480</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>442480</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>8.8</classPercent>
<typeOfReportingPerson>PN</typeOfReportingPerson>
<comments>The reporting person's ownership consists of 442,480 warrants to purchase shares of common stock (the "Warrants"). Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Lind Global Partners II LLC</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>442480</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>442480</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>442480</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>8.8</classPercent>
<typeOfReportingPerson>OO</typeOfReportingPerson>
<comments>The reporting person's ownership consists of 442,480 Warrants. Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>EASTON JEFF</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>X1</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>442480</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>442480</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>442480</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>8.8</classPercent>
<typeOfReportingPerson>IN</typeOfReportingPerson>
<comments>The reporting person's ownership consists of 442,480 Warrants. Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>TENAX THERAPEUTICS, INC.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina, 27517</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"):&#13;
&#13;
    o     Lind Global Fund II LP, a Delaware limited partnership;&#13;
    o     Lind Global Partners II LLC, a Delaware limited liability company; and&#13;
    o     Jeff Easton, an individual and a citizen of the United States of America.&#13;
&#13;
Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.&#13;
&#13;
Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>The address of the principal business office for each of the Reporting Persons is:&#13;
&#13;
444 Madison Ave, Floor 41 &#13;
New York, NY 10022</principalBusinessOfficeOrResidenceAddress>
<citizenship>See Row 4 of cover page for each Reporting Person.</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>See Row 9 of cover page for each Reporting Person.</amountBeneficiallyOwned>
<classPercent>See Row 11 of cover page for each Reporting Person.</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>See Row 5 of cover page for each Reporting Person.</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>See Row 6 of cover page for each Reporting Person.</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>See Row 7 of cover page for each Reporting Person.</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>See Row 8 of cover page for each Reporting Person.</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>Lind Global Fund II LP</reportingPersonName>
<signatureDetails>
<signature>By: Lind Global Partners II LLC, its General Partner, By: /s/ Jeff Easton</signature>
<title>Jeff Easton, Managing Member</title>
<date>11/14/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Lind Global Partners II LLC</reportingPersonName>
<signatureDetails>
<signature>/s/ Jeff Easton</signature>
<title>Jeff Easton, Managing Member</title>
<date>11/14/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>EASTON JEFF</reportingPersonName>
<signatureDetails>
<signature>/s/ Jeff Easton</signature>
<title>Jeff Easton</title>
<date>11/14/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
